Pharmacotherapy & Pipeline

GLP-1 Medications & Hair Loss

Why hair shedding shows up on semaglutide and tirzepatide, what the data actually show, and how to handle it — without derailing a therapy that's working.

Reviewed by Doug Maready, MD
A plain-language guide to what the research shows

By the numbers

5.3%

of people who lost >20% of their body weight reported hair loss — vs 2.5% of those who lost less. It tracks how much and how fast you lose weight, not the medication itself.

Wegovy (semaglutide) product monograph, Novo Nordisk, 2024

Core Concepts

Six things to know about this hair loss.

Tap any card for a clear, plain-language summary of what's known.

Telogen Effluvium 101

The medical name for the temporary, reversible shedding behind almost all GLP-1 hair loss. Your follicles aren't being destroyed.

Read pearls

Why It Happens

It's driven by fast, significant weight loss and the nutrition gaps that come with it — not the drug attacking your hair.

Read pearls

What the Studies Show

In the big clinical trials it was uncommon, usually mild, and more often reported by women.

Read pearls

What Real Life Shows

Outside the studies, it gets reported a bit more often — especially by women who lose weight quickly.

Read pearls

The Regrowth Surprise

For some people, these medications have actually improved hair. Follicles carry GLP-1 receptors — so the effect can go either way.

Read pearls

What You Can Do

Knowing it's temporary — and what supports regrowth — makes the wait a lot easier.

Read pearls

For Clinicians

Two clinical workflows.

For healthcare professionals — these open detailed walkthroughs with step-by-step reasoning.

Evaluation & Workup

The patient says their hair is falling out. Confirm the pattern, time the onset, order the right labs, and know the red flags. Click each step to expand.

Open walkthrough

Management & Prevention

Nutrition, micronutrients, titration, minoxidil, and time — compared, with when (and when not) to stop the GLP-1.

Open walkthrough

The Basics

Telogen Effluvium 101

When your body goes through a big change, a wave of hair follicles shifts from growing to resting all at once — and then sheds. It looks alarming, but it almost always grows back.

Your hair naturally cycles through growing, resting, and shedding phases
A big change — like rapid weight loss — pushes many follicles into the shedding phase at the same time
The shedding is delayed: it usually shows up 2–4 months after the change that triggered it
It thins evenly across your whole scalp — not in patches or a receding hairline
The follicles survive, so your hair regrows once things settle down
Most people recover within a few months — though, like the shedding, visible regrowth takes a little time to catch up

The takeaway

This is your hair reacting to a change, not a disease of the follicle. That's exactly why it's temporary.

References

Cleveland Clinic. Telogen Effluvium (Diseases & Conditions). 2023.

Alsuwailem OA et al. Cureus. 2025;17(9):e92454.

Why It Happens

Why It Happens on GLP-1s

The medication isn't attacking your hair. The real trigger is fast, significant weight loss — the same thing that causes shedding after weight-loss surgery or crash diets.

The main driver is how fast and how much weight you lose — not a direct effect on the hair
The same shedding happens after weight-loss surgery, very low-calorie diets, and serious illness
Eating much less can leave you short on protein, iron, zinc, and vitamin D — all of which your hair needs
The more weight you lose, the more likely it is: about 5.3% of people who lost over 20% of their weight reported it, vs 2.5% who lost less
There's no evidence the medications are toxic to hair follicles themselves
People who lose weight faster tend to notice more shedding

The takeaway

Losing weight a bit more gradually, while eating well, is the part you can control. The drug isn't poisoning your hair — the pace of weight loss is stressing it.

References

Alsuwailem OA et al. Cureus. 2025;17(9):e92454.

Wegovy product monograph. Novo Nordisk; 2024.

Haykal D. J Cosmet Dermatol. 2025;24:e70125.

What the Studies Found

What the Studies Show

In the large clinical trials, hair loss was uncommon, usually mild, and rarely the reason anyone stopped the medication.

STEP 1 (semaglutide / Wegovy): hair loss reported by 3% of people, vs 1% on placebo
SURMOUNT-1 (tirzepatide / Zepbound): about 5%, vs 0.9% on placebo
It was reported mostly by women (the studies were about two-thirds women)
When it happened, it was usually mild and rarely a reason people quit
Real-life rates may run a little higher, since people often lose weight faster than in studies
Older medications in this family show little or no hair-loss signal

The takeaway

Real, but uncommon — affecting a small share of people, more often women, and usually mild.

References

Wilding JPH et al. N Engl J Med. 2021;384(11):989–1002.

Jastreboff AM et al. N Engl J Med. 2022;387(3):205–216.

Beyond the Studies

What Real Life Shows

Reports from everyday use show hair loss a bit more often than the studies did — especially with the newer, stronger medications and in women.

In an FDA safety-report database, hair loss came up about 2.5× more than expected for semaglutide and 1.7× for tirzepatide
Compared with women on metformin, women starting semaglutide had about 1.4× the risk
Compared with another weight-loss medication, women on semaglutide had roughly twice the rate of hair loss — still affecting a minority
One clinic's records linked semaglutide most strongly to shedding, with tirzepatide more weakly
People in real life often lose weight faster than in studies, which fits with more shedding
The true numbers are uncertain — hair loss often goes unmentioned unless someone asks

The takeaway

In everyday use it shows up somewhat more often — mostly in women and fast responders — but it still affects a minority, and it's the temporary, reversible kind.

References

Godfrey H et al. J Eur Acad Dermatol Venereol. 2025;39 (FAERS 2022–2023).

Desai DD et al. Int J Dermatol. 2024;63:1128–1130.

Burke O et al. J Am Acad Dermatol. 2025;92:1141–1143.

Risk of Hair Loss with Semaglutide (cohort). medRxiv preprint. 2025.

The Other Side

The Regrowth Surprise

The story isn't all one way. Some people's hair has actually improved on these medications — a reminder that your overall health and your hair are connected.

These medications act on receptors that are also found in skin and around hair follicles
Switching on those receptors may send a "grow" signal to the follicle
In published cases, tirzepatide improved certain hair-loss conditions
Longer treatment was linked to regrowth in one scarring type of hair loss
Likely reasons: better blood sugar, insulin sensitivity, and blood flow to the scalp
For any one person, the result is a balance of fast-weight-loss shedding vs these health benefits

The takeaway

For some people, improving their overall health helps their hair. The evidence is still early, but it's a good reason not to assume the medication is automatically to blame.

References

List JF, He H, Habener JF. Regul Pept. 2006;134:149–157.

Gordon ER et al. JAAD Case Rep. 2024;50:123–125.

Morrissette K et al. Cureus. 2024;16:e76267.

Desir N et al. J Am Acad Dermatol. 2025;93:771–773.

What Helps

What You Can Do

Hair loss is one of the top reasons people quietly stop these medications. Knowing what to expect — and what supports your hair — makes it much easier to ride out.

Eat enough protein and don't let your overall nutrition slide as your appetite drops
Don't be surprised by the timing — shedding usually starts 2–4 months in, not right away
It's temporary — hair typically regrows within months once your weight steadies
Remember the cause is the pace of weight loss, not the drug harming you
This is different from gradual, patterned (genetic) thinning
Tell your clinician if loss is patchy, leaves smooth bald spots, or comes out very fast — that's not ordinary shedding

The takeaway

Knowing it's coming and temporary is half the battle. People who expect a brief shed ride it out — those caught off guard often quit a treatment that's working.

References

Alsuwailem OA et al. Cureus. 2025;17(9):e92454.

Desai DD et al. Int J Dermatol. 2024;63:1128–1130.

GLP-1 & Hair Loss / Evaluation & Workup

Clinical Algorithm

Evaluating the Patient Who Reports Shedding

Most GLP-1–associated hair loss is telogen effluvium — diffuse, delayed, and reversible. The job is to confirm that, rule out mimics, and catch the rare patient who needs dermatology. Click each step to expand.

01Characterize the pattern

Diffuse thinning across the whole scalp, more hair in the brush and drain, widening of the part without a bald patch → consistent with telogen effluvium.

Patchy, well-defined loss suggests alopecia areata. Scarring (smooth, shiny scalp, loss of follicular openings) is a different and more urgent category. Gradual crown/temporal recession is androgenetic and predates the medication.

02Time the onset against the weight curve

Telogen effluvium surfaces 2–4 months after the trigger. Map the shedding onset onto the dose-escalation and weight-loss trajectory.

Ask: how much weight, how fast? A steep loss curve in the preceding months is the expected setup. Shedding that began before any weight change points elsewhere.

03Take a nutrition & intake history

GLP-1 appetite suppression can quietly drop protein and overall intake well below target. Quantify daily protein, overall calories, and any nausea-driven food avoidance.

Inadequate protein and micronutrient intake is both a contributor and the most modifiable one.

04Check labs for correctable contributors

Reasonable panel: ferritin / iron studies, TSH, vitamin D, vitamin B12, zinc, CBC, and a marker of protein status (albumin/prealbumin).

Low ferritin and thyroid dysfunction are common, treatable amplifiers of shedding. In women with a patterned component, consider androgen evaluation.

Caveat: high-dose biotin supplements can interfere with several lab immunoassays — ask about them and hold before testing.

05Separate telogen effluvium from its mimics

A gentle hair pull test positive across multiple scalp regions supports diffuse effluvium. Androgenetic alopecia shows miniaturization in a patterned distribution and a longer timeline.

Remember the paradox: in some patients GLP-1 therapy coincides with hair improvement. New patterned loss isn't automatically the drug.

06Know the red flags for referral

Refer to dermatology for: scarring appearance, patchy loss, rapidly progressive or near-total loss, scalp symptoms (pain, pustules, itch), or shedding that doesn't stabilize after weight plateaus and labs are corrected.

Final synthesis

Diffuse shedding, onset 2–4 months after rapid weight loss, non-scarring, normal or correctable labs = telogen effluvium. Confirm the pattern, fix the deficiencies, reassure — and refer only the mimics.

GLP-1 & Hair Loss / Management & Prevention

Management Strategy

Managing & Preventing GLP-1 Hair Loss

There's no drug to "cure" telogen effluvium — the goal is to remove the stressors, support the follicle, and buy time. Most of the work is nutritional and educational; minoxidil and discontinuation are the exceptions, not the default.

First-line levers

Protein adequacy

~1.0–1.5 g/kg ideal body weight; don't let intake collapse with appetite

+ Targets the most common and most modifiable contributor

– Requires deliberate planning against GLP-1 appetite suppression

Micronutrient repletion

Replace iron (if ferritin low), vitamin D, B12, zinc; treat thyroid dysfunction

+ Corrects amplifiers; cheap and low-risk when guided by labs

– Supplement only documented deficiencies; biotin can skew assays

Moderate the titration

Slow dose escalation to temper the rate of weight loss

+ Addresses the actual driver — speed and magnitude of loss

– Trades a faster weight result for a gentler follicular course

Time & reassurance

Expect recovery over months once weight stabilizes

+ The condition is self-limited; most patients regrow

– Visible improvement lags; the wait itself drives anxiety

When more is warranted

Topical / low-dose oral minoxidil

Best-studied pharmacologic option for telogen effluvium; LDOM start ~1.25 mg (women) / 2.5 mg (men)

+ Can shorten and soften a prolonged or distressing shed

– Off-label here; LDOM needs clinician oversight and monitoring

Dermatology referral

For scarring, patchy, refractory, or diagnostically unclear loss

+ Catches mimics that aren't simple effluvium

– Unnecessary for the typical diffuse, self-limited case

The discontinuation question

01Don't stop the GLP-1 reflexively

The shedding is usually self-limited and the metabolic, cardiovascular, and weight benefits are substantial. For most patients, the right move is support-and-wait, not withdrawal.

Stopping doesn't reverse already-committed telogen hairs quickly — the shed in progress will still play out.

02Reserve dose reduction / pause for refractory distress

If shedding is severe, prolonged, and a major source of distress despite nutrition and time, slowing titration or a temporary dose reduction is reasonable — weighed explicitly against losing disease control.

Make it a shared decision and document the trade-off.

Practical pearl

Protein + targeted micronutrient repletion + measured titration + time covers the great majority. Add minoxidil for the persistent or distressing case; reserve discontinuation for refractory shedding where the patient's distress outweighs the metabolic benefit.

References

Alsuwailem OA et al. Cureus. 2025;17(9):e92454.

Randolph M, Tosti A. J Am Acad Dermatol. 2021;84(3):737–746 (low-dose oral minoxidil).

Haykal D. J Cosmet Dermatol. 2025;24:e70125.